Status: Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Participants needed: 45
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jul 13, 2026Locations: 18
Eligibility criteria
Subjects must be at least 18 years of age [+12]
Any another primary malignancy within the 3 years prior to enrollment [+18]